Blueprint Medicines Corp
BPMC128.550USD
+0.150+0.12%
종가 07/09, 16:00（ET）시세는 15분 지연됩니다
8.30B시가총액
손실P/E TTM
자세한 내용은 Blueprint Medicines Corp 회사
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
회사 정보
종목 코드 BPMC
회사 이름Blueprint Medicines Corp
상장일Apr 30, 2015
설립일2008
CEOMs. Kathryn D (Kate) Haviland
직원 수649
유형Ordinary Share
회계 연도 종료Apr 30
주소45 Sidney Street
도시CAMBRIDGE
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호02139
전화16173747580
웹사이트https://www.blueprintmedicines.com/
종목 코드 BPMC
상장일Apr 30, 2015
설립일2008
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Chairman of the Board
Chairman of the Board
146.41K
+2.74%
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
43.17K
+20.54%
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
42.00K
+20.92%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
18.22K
-6.04%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.38K
-6.40%
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
Lead Independent Director
Lead Independent Director
14.91K
+35.43%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Chairman of the Board
Chairman of the Board
146.41K
+2.74%
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
43.17K
+20.54%
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
42.00K
+20.92%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
수익 분석
통화: USD마지막 업데이트: Sun, Apr 6
통화: USD마지막 업데이트: Sun, Apr 6
FY2024Q3
FY2024Q2
FY2024Q1
사업별USD
이름
수익
비율
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
지역별USD
이름
수익
비율
United States
113.13M
88.26%
Rest of the world
15.05M
11.74%
사업별
지역별
사업별USD
이름
수익
비율
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
주식 보유 통계
마지막 업데이트: Fri, May 16
마지막 업데이트: Fri, May 16
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
10.25%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.57%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
Other
63.20%
주주
주주
비율
The Vanguard Group, Inc.
10.25%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.57%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
Other
63.20%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
50.09%
Investment Advisor
44.11%
Hedge Fund
8.89%
Research Firm
2.98%
Individual Investor
1.11%
Sovereign Wealth Fund
1.10%
Venture Capital
0.77%
Pension Fund
0.56%
Bank and Trust
0.49%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
686
71.41M
110.43%
-1.17M
2025Q1
702
71.75M
110.98%
-1.27M
2024Q4
657
69.17M
108.25%
-2.83M
2024Q3
644
67.12M
105.97%
-7.85M
2024Q2
622
68.23M
108.95%
-6.94M
2024Q1
615
67.81M
110.73%
-5.62M
2023Q4
612
65.87M
108.35%
-10.02M
2023Q3
602
66.47M
109.56%
-7.64M
2023Q2
614
65.78M
108.78%
-8.60M
2023Q1
625
65.63M
109.42%
-10.28M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
6.63M
10.25%
-134.36K
-1.99%
Mar 31, 2025
T. Rowe Price Associates, Inc.
5.35M
8.28%
-266.46K
-4.74%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.89M
7.57%
-106.17K
-2.12%
Mar 31, 2025
Avoro Capital Advisors LLC
3.85M
5.95%
+2.67M
+224.89%
Mar 31, 2025
Wellington Management Company, LLP
3.07M
4.75%
-1.21M
-28.22%
Mar 31, 2025
State Street Global Advisors (US)
2.68M
4.15%
+183.91K
+7.36%
Mar 31, 2025
JP Morgan Asset Management
2.03M
3.15%
+1.33M
+187.97%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.52M
2.35%
+32.55K
+2.18%
Mar 31, 2025
William Blair Investment Management, LLC
1.43M
2.21%
-515.03K
-26.48%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
1.30M
2.01%
+605.78K
+86.91%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sun, Jul 6
마지막 업데이트: Sun, Jul 6
이름
비율
Invesco Biotechnology & Genome ETF
3.22%
Tema Oncology ETF
2.73%
SPDR S&P Biotech ETF
2.04%
Motley Fool Small-Cap Growth ETF
1.6%
Direxion Daily S&P Biotech Bull 3X Shares
1.47%
American Century Focused Dynamic Growth ETF
1.32%
JPMorgan Fundamental Data Science Small Core ETF
1.1%
ProShares Ultra Nasdaq Biotechnology
0.94%
Hypatia Women CEO ETF
0.8%
Invesco Nasdaq Biotechnology ETF
0.73%
더 보기
Invesco Biotechnology & Genome ETF
비율3.22%
Tema Oncology ETF
비율2.73%
SPDR S&P Biotech ETF
비율2.04%
Motley Fool Small-Cap Growth ETF
비율1.6%
Direxion Daily S&P Biotech Bull 3X Shares
비율1.47%
American Century Focused Dynamic Growth ETF
비율1.32%
JPMorgan Fundamental Data Science Small Core ETF
비율1.1%
ProShares Ultra Nasdaq Biotechnology
비율0.94%
Hypatia Women CEO ETF
비율0.8%
Invesco Nasdaq Biotechnology ETF
비율0.73%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
